Leerink Partnrs Issues Positive Forecast for Bruker Earnings

Bruker Corporation (NASDAQ:BRKR) – Research analysts at Leerink Partnrs increased their Q2 2026 earnings per share (EPS) estimates for shares of Bruker in a research report issued to clients and investors on Monday, November 3rd. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of $0.48 per share for the quarter, up from their prior estimate of $0.45. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker’s Q3 2026 earnings at $0.62 EPS, FY2026 earnings at $2.44 EPS and FY2027 earnings at $2.84 EPS.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. The firm had revenue of $860.50 million during the quarter, compared to analysts’ expectations of $847.40 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS.

A number of other equities research analysts have also recently issued reports on BRKR. TD Cowen boosted their price objective on Bruker from $40.00 to $42.00 and gave the stock a “hold” rating in a report on Tuesday. Citigroup reduced their price target on Bruker from $40.00 to $38.00 and set a “neutral” rating for the company in a research note on Monday, August 4th. UBS Group increased their price objective on Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a research report on Tuesday. Cowen reissued a “hold” rating on shares of Bruker in a report on Tuesday. Finally, Stifel Nicolaus set a $40.00 price target on shares of Bruker and gave the company a “hold” rating in a research note on Tuesday, August 5th. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Bruker has a consensus rating of “Hold” and an average price target of $48.30.

Bruker Stock Down 2.2%

Shares of BRKR opened at $39.31 on Thursday. Bruker has a 52 week low of $28.53 and a 52 week high of $64.64. The firm has a market cap of $5.96 billion, a P/E ratio of 75.60, a price-to-earnings-growth ratio of 5.31 and a beta of 1.26. The firm’s 50-day simple moving average is $34.90 and its 200 day simple moving average is $37.05. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Monday, December 8th. Bruker’s dividend payout ratio is presently -125.00%.

Insider Buying and Selling

In other news, Director Cynthia M. Friend sold 3,535 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the transaction, the director directly owned 18,016 shares in the company, valued at approximately $581,016. The trade was a 16.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 27.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Orbis Allan Gray Ltd bought a new stake in Bruker during the second quarter worth $192,735,000. AQR Capital Management LLC lifted its position in shares of Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after buying an additional 1,850,215 shares during the last quarter. Sculptor Capital LP boosted its stake in Bruker by 18.3% in the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock valued at $126,682,000 after buying an additional 476,363 shares in the last quarter. Brown Advisory Inc. grew its position in Bruker by 13.9% in the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock valued at $113,142,000 after acquiring an additional 336,026 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. raised its stake in Bruker by 61.6% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock worth $67,909,000 after acquiring an additional 796,510 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.